Education
About Us
Working with TipRanks
Follow Us
Genscript Biotech (HK:1548)
:1548
Total Valuation
Genscript Biotech has a market cap or net worth of $38.39B. The enterprise value is HK$26.12B.
Market Cap$38.39B
Enterprise ValueHK$26.12B
Share Statistics
Genscript Biotech has 2,185,099,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,185,099,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genscript Biotech’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 0.19%.
Return on Equity (ROE)0.69
Return on Assets (ROA)0.56
Return on Invested Capital (ROIC)0.19%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee106.77K
Profits Per Employee531.95K
Employee Count5,568
Asset Turnover0.11
Inventory Turnover10.37
Valuation Ratios
The current PE Ratio of Genscript Biotech is 1.0. Genscript Biotech’s PEG ratio is -0.03.
PE Ratio1.0
PS Ratio4.64
PB Ratio0.64
Price to Fair Value0.64
Price to FCF-38.16
Price to Operating Cash Flow58.61
PEG Ratio-0.03
Income Statement
In the last 12 months, Genscript Biotech had revenue of 594.49M and earned 2.96B in profits. Earnings per share was -0.03.
Revenue594.49M
Gross Profit272.13M
Operating Income9.28M
Pretax Income-170.80M
Net Income2.96B
EBITDA70.43M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was 232.62M and capital expenditures -32.13M, giving a free cash flow of 200.49M billion.
Operating Cash Flow232.62M
Free Cash Flow200.49M
Free Cash Flow per Share0.09
Dividends & Yields
Genscript Biotech pays an annual dividend of HK$0.012, resulting in a dividend yield of ―
Dividend Per ShareHK$0.012
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change34.21%
50-Day Moving Average17.26
200-Day Moving Average13.65
Relative Strength Index (RSI)47.44
Average Volume (3m)12.47M
Important Dates
Genscript Biotech upcoming earnings date is Mar 27, 2026, TBA (Confirmed).
Last Earnings DateAug 17, 2025
Next Earnings DateMar 27, 2026
Ex-Dividend DateJun 05, 2017
Financial Position
Genscript Biotech as a current ratio of 2.72, with Debt / Equity ratio of 16.75%
Current Ratio2.72
Quick Ratio2.62
Debt to Market Cap0.24
Net Debt to EBITDA8.40
Interest Coverage Ratio1.16
Taxes
In the past 12 months, Genscript Biotech has paid 2.98M in taxes.
Income Tax2.98M
Effective Tax Rate-0.02
Enterprise Valuation
Genscript Biotech EV to EBITDA ratio is 47.57, with an EV/FCF ratio of -46.35.
EV to Sales5.64
EV to EBITDA47.57
EV to Free Cash Flow-46.35
EV to Operating Cash Flow44.28
Balance Sheet
Genscript Biotech has $938.36M in cash and marketable securities with $548.52M in debt, giving a net cash position of $389.84M billion.
Cash & Marketable Securities$938.36M
Total Debt$548.52M
Net Cash$389.84M
Net Cash Per Share$0.18
Tangible Book Value Per Share$1.98
Margins
Gross margin is 45.77%, with operating margin of 1.56%, and net profit margin of 498.22%.
Gross Margin45.77%
Operating Margin1.56%
Pretax Margin-28.73%
Net Profit Margin498.22%
EBITDA Margin11.85%
EBIT Margin1.56%
Analyst Forecast
The average price target for Genscript Biotech is $23.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$23.96
Price Target Upside40.31% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―